# Treatment Methods for Autoimmune Hepatitis
In advanced autoimmune hepatitis, suppression of the inflamed immune response is central. Treatment aims to counteract inflammation activity in the liver, prevent scarring (fibrosis), and, where possible, reverse existing scar tissue formation. Which medications and combinations are used depends on the severity of the disease, how well the body responded to previously given medications, and whether complications such as portal hypertension (elevated blood pressure in the portal vein) have already occurred.
Corticosteroids
ProveniIncluded in official guidelines, or approved by EMA or FDA
Corticosteroids (usually prednisone or prednisolone) have been the cornerstone of treatment for decades. They suppress the overreaction of the immune system by inhibiting the activation of inflammatory cells.
*How it works:* The substance binds to receptors in body cells and inhibits the production of inflammatory molecules. This leads to less attack on liver tissue.
*Side effects (general):* Long-term use can lead to weight gain, bone demineralization (osteoporosis), mood swings, sleep disturbances, elevated blood sugar, increased susceptibility to infection, and thinning skin. These adverse effects do not always occur and vary from person to person. Regular comprehensive examination helps detect risks early.
In advanced disease with liver scarring, whether corticosteroids can be given depends on the stage of liver cirrhosis. Recent attention focuses on the balance between inflammation suppression and the risk of infections in people with very severe liver damage.
Azathioprine (AZA)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This medication inhibits the multiplication of certain immune cells. It is usually added to corticosteroids, so the corticosteroid dose can be reduced.
*How it works:* Azathioprine disrupts the division of T-cells and B-cells, which drive the autoimmune attack.
*Side effects (general):* Nausea, abdominal pain, reduced production of blood cells (with increased infection risk), and in rare cases pancreatitis. Regular blood tests monitor these effects.
Mycophenolate mofetil (MMF)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This medication is used when patients do not tolerate azathioprine or do not respond to it. It works by inhibiting an important enzyme in the multiplication of certain immune cells.
*How it works:* MMF selectively inhibits the production of guanosine in T- and B-cells, slowing their growth.
*Side effects (general):* Diarrhea, nausea, headache, anemia. Some women have a slightly increased miscarriage risk in the first trimester, which requires discussion with the doctor.
Thiopurine S-methyltransferase (TPMT) Testing
ProveniIncluded in official guidelines, or approved by EMA or FDA
Before starting azathioprine or certain forms of 6-mercaptopurine, blood tests are performed to check for the TPMT enzyme. People with low enzyme activity are at risk of severe toxicity.
*How it works:* This is not a treatment itself, but a safety test. Those without sufficient TPMT cannot use these medications or can only use them in much lower doses.
Tacrolimus
ResearchediPositive results in clinical studies, not yet standard treatment
This medication, originally developed for transplant patients, suppresses the immune response. Studies suggest usefulness in people who do not respond to standard treatment.
*How it works:* Tacrolimus binds to certain immune cells and disrupts their signaling, blocking their activation.
*Side effects (general):* Tremors, headache, kidney function disorders, elevated blood sugar, neurological symptoms. Blood levels must be monitored closely.
Anti-TNF Therapy (Tumor Necrosis Factor Inhibitors)
ResearchediPositive results in clinical studies, not yet standard treatment
TNF is an important inflammatory molecule. Medications that block TNF (infliximab, etanercept, adalimumab, etc.) are successful in other autoimmune diseases. Recent publications emphasize possible benefits also in autoimmune hepatitis, especially in persistence despite standard therapy.
*How it works:* They bind to TNF molecules or their receptors and prevent inflammatory signals from spreading throughout the body.
*Side effects (general):* Increased risk of infection (including tuberculosis and certain fungi), reactions at the injection site, sexual dysfunction and, very rarely, inflammation of the nervous system. Screening tests for infections are necessary.
Rituximab
ResearchediPositive results in clinical studies, not yet standard treatment
This agent targets B cells, which produce antibodies that attack the liver. Case reports show response in autoimmune liver diseases that are resistant to standard therapy.
*How it works:* Rituximab binds to CD20, a protein on B cells, thereby disabling these cells.
*Side effects (general):* Infusion-related reactions (chills, fever), susceptibility to infection (especially opportunistic infections), possible reactivation of latent viral infections. Patients must be tested for certain infections beforehand.
Ursodeoxycholic acid (UDCA)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This bile-like substance can be given as a supplement to immunosuppressants, especially if there are signs of cholestasis (bile stasis).
*How it works:* UDCA protects liver cells against bile acid damage, promotes bile excretion and has anti-inflammatory effects.
*Side effects (general):* Diarrhea is the most common. Overall it is well tolerated.
Budesonide (in specific situations)
ResearchediPositive results in clinical studies, not yet standard treatment
This is a corticosteroid with stronger local action in the intestine and liver, and weaker systemic effects. It could have benefits in mild to moderately severe disease without liver cirrhosis.
*How it works:* Budesonide concentrates in the liver and intestine with less exposure in the blood, which may mean fewer systemic side effects.
*Side effects (general):* Similar to other corticosteroids, but usually less severe. Not yet established as standard for autoimmune hepatitis.
Adebrelimab
ExperimentaliOngoing in study setting, outcome still unknown
This is an experimental agent that disables CD25+ immune cells (especially activated T cells). Some case reports describe autoimmune-like liver damage after exposure, which underscores the investigation of side effect mechanisms.
*How it works:* It is intended to target the IL-2 receptor pathway in activated T cells.
*Side effects:* Not yet fully established; early reports emphasize the risk of unexpected liver damage.
Artificial liver support and transplantation
ProveniIncluded in official guidelines, or approved by EMA or FDA
(for end-stage disease)
In acute liver failure despite immunosuppression or in advanced cirrhosis with decompensation, artificial support (ECMO, MARS, dialysis-like devices) can provide bridging therapy. Liver transplantation is the treatment for terminal-stage disease.
*Purpose:* Remove toxic substances that the diseased liver can no longer process, until recovery occurs or transplantation is possible.
*Risks and considerations:* Infection, bleeding, loss of kidney function. Transplantation requires lifelong immunosuppression and other long-term risks, but can be life-saving.
Monitoring and adjustments
Regardless of which treatment is started, regular monitoring is essential. Liver enzymes (ALT, AST), bilirubin, clotting factors and blood cell counts are determined repeatedly. Imaging (ultrasound, elastography) monitors scarring. Not all patients respond to the same medicines; therefore, doctors adjust the strategy based on laboratory and clinical response, balancing inflammation suppression against side effect risk.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._